(Q37810237)

23 August 2017

title

Microdosing: current and the future (English)

1 reference

23 August 2017

Graham Lappin

1

1 reference

23 August 2017

publication date

1 March 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

509-517

1 reference

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Microdosing in early lead discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

New ultrasensitive detection technologies and techniques for use in microdosing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

The hepatic first-pass metabolism of problematic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.09.177

21 January 2018

Identifiers

DOI

10.4155/BIO.09.177

1 reference

23 August 2017

1 reference